Food – Talk Bio

Sarepta Sells $174 Million Stake in Arrowhead to Fund Milestone Payment Amid Cash Crunch

4 weeks ago talkbio0Tagged Arrowhead, Cash Crunch, Collaboration, milestone payment, Myotonic Dystrophy, private block trade, RNA Interference, SRP-1003, stake sale

Sarepta Therapeutics; Arrowhead Pharmaceuticals; cash crunch; stake sale; milestone payment; RNAi collaboration; SRP-1003; myotonic dystrophy; private block trade

Sanofi Acquires China Rights to Arrowhead’s Plozasiran for $395 Million

1 month ago talkbio0Tagged Arrowhead, China, Familial chylomicronemia syndrome, Hypertriglyceridemia, milestone payments, Partnership, Plozasiran, RNA Interference, sanofi, Severe (severity modifier)

Sanofi; Arrowhead Pharmaceuticals; Visirna Therapeutics; Plozasiran; China rights; RNA interference; Familial chylomicronemia syndrome; Severe hypertriglyceridemia; biotech partnership; milestone payments

FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts

4 months ago talkbio0Tagged Agencies, Approved, Impact food supplement, PDUFA, questions, United States Food and Drug Administration

United States Food and Drug Administration, PDUFA, Impact food supplement, Approved, Agencies, questions

Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss

5 months ago talkbio0Tagged Diabetes Mellitus, Non-Insulin-Dependent, Glucagon-Like Peptide 1, Hemoglobin A1c measurement, Injectables, Oral cavity, orforglipron, Phase 3 Clinical Trials, Safety, Weight Loss

orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables

Former FDA Officials Sound Alarm: Visible Changes May Be Tip of the Iceberg

5 months ago talkbio0Tagged Alarm device, Changing, Disease Outbreaks, drug safety, Icebergs, KAT5 wt Allele, Leadership, Policy, Previous, public health medicine (field), United States Food and Drug Administration, Vaccines, Visible

United States Food and Drug Administration, public health medicine (field), Changing, Vaccines, Leadership, Policy, drug safety, Previous, KAT5 wt Allele, Icebergs, Disease Outbreaks, Alarm device, Visible

U.S. Biotechs Reveal Tariff Exposure as Trade Inquiry Signals Imminent Pharmaceutical Tariffs

5 months ago talkbio0Tagged Evaluation, global supply chain, Impact food supplement, Import, Manufacturing, pharmaceutical ingredients, pharmaceutical tariffs, Policy, regulatory, reshoring, Sectioning technique, supply chain exposure, TNFRSF19 gene, United States

U.S. biotech, pharmaceutical tariffs, Section 232 investigation, supply chain exposure, trade policy, import costs, reshoring manufacturing, drug pricing, global supply chain, pharmaceutical ingredients, regulatory impact

Trump Announces Imminent Major Tariffs on Pharmaceuticals: Implications for Global Markets and U.S. Manufacturing

5 months ago talkbio0Tagged drug price, Impact food supplement, Pharma import taxes, pharmaceutical manufacturing, Pharmaceutical stocks, pharmaceutical tariffs, Policy, Relations, TNFRSF19 gene, Transplant Registry Unified Management Program, U.S.-China, United States

Trump pharmaceutical tariffs, U.S. pharmaceutical manufacturing, Pharma import taxes, Drug price impact, Trade policy 2025, U.S.-China trade relations, Pharmaceutical stocks

Trump Tariffs Poised to Hit Drug Tool and Packaging Manufacturers: Industry Faces Rising Costs and Supply Chain Challenges

5 months ago talkbio0Tagged alpha 1-antitrypsin, Biopharma trade war, Drug Industry, Drug packaging industry, Generic Drugs, Impact food supplement, lobbying, Manufacturing, Market, onshoring, Pharmaceutical Supply Chain, pharmaceutical tariffs, Supply chain disruption, Trump tariffs, U.S., United States

Trump tariffs , Drug packaging industry , Pharmaceutical supply chain , API manufacturing costs , Biopharma trade war , U.S. manufacturing onshoring , Generic drugs market impact , Pharmaceutical tariffs , Supply chain disruption , Pharmaceutical industry lobbying

A closer look at pharmas top patent losses in 2025

6 months ago talkbio0Tagged 2023, 2025, Bayer, competition, Expiration, function, Impact food supplement, Indication of (contextual qualifier), Legal patent, Market, Patent Cliff, Regeneron, Sales - occupational activity

Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023

Opko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinic

6 months ago talkbio0Tagged entera, first, GLP-1/glucagon, OPKO, Oral cavity, Ownership

entera, GLP-1/glucagon, first, Oral cavity, OPKO, Ownership, Entera